Current Report Filing (8-k)
February 04 2021 - 02:25PM
Edgar (US Regulatory)
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549
FORM 8-K
CURRENT REPORT
Pursuant to Section 13 or 15(d) of The Securities Exchange Act
of 1934
Date of Report (Date of Earliest Event Reported): February 1,
2021
Titan Pharmaceuticals,
Inc.
(Exact name of registrant as specified in its charter)
Delaware
(State or other jurisdiction of incorporation)
001-13341 |
94-3171940 |
(Commission File Number) |
(IRS Employer Identification No.) |
400 Oyster Point Blvd., Suite 505, South San Francisco,
CA 94080
(Address of principal executive offices and zip code)
650-244-4990
(Registrant's telephone number including area code)
(Registrant's former name or former address, if changed since last
report)
Securities registered pursuant to Section 12(b) of the
Act:
Title
of each class |
Trading
Symbol |
Name
of each exchange on which registered |
Common
Stock, $0.001 par value |
TTNP |
Nasdaq
Capital Market |
Check the appropriate box below if the Form 8-K filing is intended
to simultaneously satisfy the filing obligation of registrant under
any of the following provisions:
|
¨ |
Written communications pursuant to Rule 425 under
the Securities Act (17 CFR 230.425) |
|
¨ |
Soliciting material pursuant to Rule 14a-12(b)
under the Exchange Act (17 CFR 240.14a-12(b)) |
|
¨ |
Pre-commencement communications pursuant to Rule
14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b)) |
|
¨ |
Pre-commencement communications pursuant to Rule
13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c)) |
Indicate by check mark whether the registrant is an emerging growth
company as defined in Rule 405 of the Securities Act of 1933
(§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange
Act of 1934 (§240.12b-2 of this chapter).
Emerging growth company ¨
If an emerging growth company, indicate by check mark if the
registrant has elected not to use the extended transition period
for complying with any new or revised financial accounting
standards provided pursuant to Section 13(a) of the Exchange Act.
¨
On February 1, 2021, Titan Pharmaceuticals, Inc. (the “Company”)
issued a press release announcing that studies of its kappa opioid
agonist peptide, JT-09, has demonstrated high potency and
specificity for the human kappa-opioid receptor. JT-09 is being
developed for use in combination with the Company’s ProNeura®
long-term, continuous drug delivery technology for the treatment of
moderate-to-severe chronic pruritus (itch). A copy of the press
release is attached hereto as Exhibit 99.1 and incorporated herein
by reference.
|
Item 9.01. |
Financial Statements and
Exhibits. |
(d) Exhibits
The following exhibit is filed herewith:
SIGNATURE
Pursuant to the requirements of the Securities Exchange Act of
1934, the registrant has duly caused this report to be signed on
its behalf by the undersigned hereunto duly authorized.
Dated: February 4,
2021 |
TITAN
PHARMACEUTICALS, INC. |
|
|
|
By: |
/s/ Kate Beebe Devarney, Ph.D. |
|
Name: |
Kate Beebe Devarney,
Ph.D. |
|
Title: |
President and Chief Operating
Officer |